95 related articles for article (PubMed ID: 18762367)
1. Adoptive T cell transfer augments IL-2 mediated tumour regression in a HNSCC xenograft nude mouse model.
Ambade A; Mulherkar R
Cancer Lett; 2008 Dec; 272(2):316-24. PubMed ID: 18762367
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
3. [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
Yang H; Liu S; Liang C; Peng W
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):9-11, 30. PubMed ID: 15600166
[TBL] [Abstract][Full Text] [Related]
4. Effect of suicide gene therapy in combination with immunotherapy on antitumour immune response & tumour regression in a xenograft mouse model for head & neck squamous cell carcinoma.
Ambade AV; Joshi GV; Mulherkar R
Indian J Med Res; 2010 Oct; 132():415-22. PubMed ID: 20966520
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
Chang CY; Lee J; Kim EY; Park HJ; Kwon CH; Joh JW; Kim SJ
BMC Cancer; 2007 May; 7():87. PubMed ID: 17519043
[TBL] [Abstract][Full Text] [Related]
6. Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma.
Liu S; Yang H; Liang C
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):323-6. PubMed ID: 12408755
[TBL] [Abstract][Full Text] [Related]
7. The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interleukin-2 in patients with squamous cell carcinoma.
Salter J; Maclennan KA; Moore J; Dadian G; Riches PG; Gore ME
J Pathol; 1995 Jun; 176(2):167-73. PubMed ID: 7636627
[TBL] [Abstract][Full Text] [Related]
8. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer.
Bray D; Yu SZ; Koprowski H; Rhee J; Kumar S; Pericle F; Suntharalingam M; Van Echo DA; Li D; O'Malley BW
Arch Otolaryngol Head Neck Surg; 2003 Jun; 129(6):618-22. PubMed ID: 12810463
[TBL] [Abstract][Full Text] [Related]
9. Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation.
Krause M; Schmitz M; Noessner E; Skrablin PS; Wehner R; Rieber EP; Baumann M
Int J Radiat Biol; 2007; 83(11-12):827-36. PubMed ID: 17852560
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
Strome SE; Kawakami K; Alejandro D; Voss S; Kasperbauer JL; Salomao D; Chen L; Maki RA; Puri RK
Clin Cancer Res; 2002 Jan; 8(1):281-6. PubMed ID: 11801570
[TBL] [Abstract][Full Text] [Related]
11. [Interleukin-2 and LAK cells in the local immunotherapy of tumors of the head and neck: an experimental model].
Sacchi M; Johnson JT; Whiteside TL; Cortesina G
Acta Otorhinolaryngol Ital; 1989; 9(4):391-8. PubMed ID: 2618654
[TBL] [Abstract][Full Text] [Related]
12. Presence of activated T lymphocytes in peripheral blood of head and neck squamous cell carcinoma patients predicts impaired prognosis.
Aarstad HJ; Heimdal JH; Klementsen B; Olofsson J; Ulvestad E
Acta Otolaryngol; 2006 Dec; 126(12):1326-33. PubMed ID: 17101596
[TBL] [Abstract][Full Text] [Related]
13. Role of nitric oxide in the development of distant metastasis from squamous cell carcinoma.
Scher RL
Laryngoscope; 2007 Feb; 117(2):199-209. PubMed ID: 17277613
[TBL] [Abstract][Full Text] [Related]
14. [IL-2 gene and cisplatin combined therapy for head and neck squamous cell carcinoma].
Liu S; Lin Y; Tang S; Yang H; Liang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2001 Jun; 19(3):191-3. PubMed ID: 12539412
[TBL] [Abstract][Full Text] [Related]
15. Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma.
Xian J; Yang H; Lin Y; Liu S
Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1079-85. PubMed ID: 16365221
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1.
van Herpen CM; Bussink J; van der Kogel AJ; Peeters WJ; van der Voort R; van Schijndel A; de Wilde PC; Adema GJ; de Mulder PH
Anticancer Res; 2005; 25(2A):1015-21. PubMed ID: 15868941
[TBL] [Abstract][Full Text] [Related]
17. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer.
Jebreel A; Mistry D; Loke D; Dunn G; Hough V; Oliver K; Stafford N; Greenman J
J Laryngol Otol; 2007 Mar; 121(3):246-52. PubMed ID: 17040593
[TBL] [Abstract][Full Text] [Related]
18. Reconstitution of nude mouse T cell function in vivo: IL 2-independent effect of human T cells.
Dosch HM; White D; Grant C
J Immunol; 1985 Jan; 134(1):336-42. PubMed ID: 3871105
[TBL] [Abstract][Full Text] [Related]
19. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC.
Williams R; Lee DW; Elzey BD; Anderson ME; Hostager BS; Lee JH
Head Neck; 2009 Jul; 31(7):911-8. PubMed ID: 19283850
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity.
Matsui M; Kishida T; Nakano H; Yoshimoto K; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Yoshimoto T; Hisa Y; Mazda O
Cancer Res; 2009 Mar; 69(6):2523-30. PubMed ID: 19244121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
